PMC

Lesion detection per imaging modality and per organ. Concordant pairs were lesions that were visualized on all three modalities. Nine PET detected lesions were outside the field of view of CT. *p < 0.001 compared to CT only

On the left are transversal sections of one patient of CT, [⁸⁹Zr]Zr-DFO-girentuximab and [¹⁸F]FDG-PET/CT. The red circle represents an adrenal gland lesion in a patient as visualized by CT (a), [⁸⁹Zr]Zr-DFO-girentuximab (b) and [¹⁸F]FDG-PET/CT (c), respectively. On the right, MIP images of [⁸⁹Zr]Zr-DFO-girentuximab (d) and [¹⁸F]FDG-PET/CT (e) are presented

A Violin plot of actual distribution of [⁸⁹Zr]Zr-DFO-girentuximab and [¹⁸F]FDG SUV_max in tumor lesions per organ site. Black vertical lines are 95% CIs of geometric mean SUVmax, white dots within black lines and values are the actual geometric means; coloured dots are individual metastases. The locations represent organ sites with at least five suspect lesions. *Compared to lung lesions, a difference was seen in the height of [⁸⁹Zr]Zr-DFO-girentuximab SUV_max values of lymph node, soft tissue, adrenal gland and kidney lesions (p < 0.05). **The height of [¹⁸F]FDG SUV_max values of kidney lesions was significantly higher compared to soft tissue lesions (p < 0.05)